Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morclofone is a synthetic small molecule drug classified as a benzophenone derivative and morpholine compound. It is primarily used as an antitussive (cough suppressant), with its main indication being the treatment of cough associated with respiratory conditions. Morclofone acts on the central nervous system to suppress the cough reflex, though its precise molecular mechanism remains incompletely characterized. It may modulate neurotransmitter release or receptor activity in the brainstem, and has been reported to interact with cholinergic pathways by inhibiting acetylcholinesterase, potentially increasing acetylcholine levels. Additionally, it exhibits some antimicrobial properties in vitro against bacteria and fungi[1][3][4][5]. The drug has reached up to Phase II clinical trials for investigational indications but does not appear to be widely marketed or approved in major regions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morclofone.